Indivisible Partners Buys Shares of 60,769 Boston Scientific Corporation $BSX

Key Points

• Indivisible Partners bought a new stake of 60,769 shares of Boston Scientific in Q4 worth about $5.79 million, and institutional investors now own roughly 89.07% of the stock with several large funds (Parnassus, Egerton, Jennison, Marshall Wace, Alphinity) significantly increasing or initiating positions.
• Boston Scientific reported Q1 EPS of $0.80 (beat by $0.01) and revenue of $5.20B (up 11.6% year-over-year), and set Q2 2026 guidance of $0.820–0.840 EPS and FY 2026 guidance of $3.340–3.410 EPS (analysts expect ~3.38 for the year).
• The stock opened at $55.98 (down ~1.5%) near its 1-year low of $55.88, trades well below its 50- and 200-day moving averages, has a market cap of about $83.2B and a consensus analyst rating of "Moderate Buy" with an average price target of $93.91.

Indivisible Partners bought a new stake in Boston Scientific Corporation (NYSE:BSX - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm bought 60,769 shares of the medical equipment provider's stock, valued at approximately $5,794,000.

Several other institutional investors also recently bought and sold shares of BSX. Parnassus Investments LLC boosted its stake in Boston Scientific by 42,978.9% in the third quarter. Parnassus Investments LLC now owns 6,884,440 shares of the medical equipment provider's stock valued at $672,128,000 after acquiring an additional 6,868,459 shares in the last quarter. Egerton Capital UK LLP boosted its stake in Boston Scientific by 223.7% in the third quarter. Egerton Capital UK LLP now owns 5,312,504 shares of the medical equipment provider's stock valued at $518,660,000 after acquiring an additional 3,671,548 shares in the last quarter. Jennison Associates LLC boosted its stake in Boston Scientific by 133.5% in the third quarter. Jennison Associates LLC now owns 4,938,746 shares of the medical equipment provider's stock valued at $482,170,000 after acquiring an additional 2,823,744 shares in the last quarter. Alphinity Investment Management Pty Ltd acquired a new stake in Boston Scientific in the fourth quarter valued at approximately $252,918,000. Finally, Marshall Wace LLP boosted its stake in Boston Scientific by 30.7% in the third quarter. Marshall Wace LLP now owns 9,799,040 shares of the medical equipment provider's stock valued at $956,680,000 after acquiring an additional 2,301,383 shares in the last quarter. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Boston Scientific Trading Down 1.5%

Shares of Boston Scientific stock opened at $55.98 on Wednesday. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.90 and a quick ratio of 1.08. The firm has a fifty day moving average price of $66.69 and a 200 day moving average price of $84.28. Boston Scientific Corporation has a 1 year low of $55.88 and a 1 year high of $109.50. The stock has a market cap of $83.20 billion, a PE ratio of 23.42, a price-to-earnings-growth ratio of 1.04 and a beta of 0.62.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.79 by $0.01. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The firm had revenue of $5.20 billion during the quarter, compared to analysts' expectations of $5.19 billion. During the same quarter last year, the company posted $0.75 earnings per share. The firm's revenue was up 11.6% compared to the same quarter last year. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Equities research analysts predict that Boston Scientific Corporation will post 3.38 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the stock. Mizuho lowered their target price on shares of Boston Scientific from $115.00 to $90.00 and set an "outperform" rating for the company in a research note on Monday, April 13th. Sanford C. Bernstein reiterated an "outperform" rating and set a $112.00 price objective on shares of Boston Scientific in a research note on Friday, February 6th. Citigroup lowered their price objective on shares of Boston Scientific from $94.00 to $87.00 and set a "buy" rating for the company in a research note on Tuesday, April 7th. Daiwa Securities Group downgraded shares of Boston Scientific from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, April 29th. Finally, BTIG Research lowered their price objective on shares of Boston Scientific from $90.00 to $80.00 and set a "buy" rating for the company in a research note on Wednesday, April 22nd. One research analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and three have given a Hold rating to the company's stock. According to MarketBeat, Boston Scientific has an average rating of "Moderate Buy" and a consensus price target of $93.91.

Boston Scientific Company Profile

Boston Scientific Corporation NYSE: BSX is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific's activities span product development, clinical research, regulatory affairs and commercial sales.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.